The following is a summary of the Paysign, Inc. (PAYS) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Paysign reported a Q2 2024 revenue of $14.3 million, a 29.8% increase year-over-year.

• Adjusted EBITDA rose significantly to $2.24 million, reflecting a 96% increase, translating to $0.04 per fully diluted share.

• Net income for the quarter was reported at $697,000, or $0.01 per fully diluted share.

Business Progress:

• The patient affordability segment experienced a 267% increase in revenue, driving significant margin expansion and contributing to 59% of total revenue growth.

• Paysign added eight new patient affordability programs in Q2, growing the total to 61 active programs.

• Eight new plasma centers were added, reaching a total of 477 centers, with plans to add 5-10 more by year-end.

Opportunities:

• Paysign's growth is driven by its expanding patient affordability and plasma donor compensation businesses.

• The company plans to continue capitalizing on opportunities through robust sales pipelines and strategic expansion into new markets.

Risks:

• The business depends significantly on the performance of its patient affordability programs and plasma donation centers.

More details: PaySign IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.